Compare Prologis Inc (PLD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prologis Inc vs Viatris Inc — how do they compare? Prologis Inc trades at $144.35 (market cap $139.79B), while Viatris Inc trades at $17.02 (market cap $20.50B). The key difference: Prologis Inc is far larger — about 6.8× Viatris Inc's market cap, and Prologis Inc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| PLD | VTRS | |
|---|---|---|
Market Cap | $139.79B | $20.50B |
Sector | Real Estate | Health |
52-Week High | $149.96 | $17.59 |
52-Week Low | $104.08 | $8.74 |
Enterprise Value | $174.47B | $32.71B |
Dividend Yield | 2.85% | 2.73% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
